Skip to main content
Clinical Trials/KCT0009107
KCT0009107
Recruiting
未知

Randomized comparison of efficacy and safety of high-intensity rosuvastatin/ezetimibe combination versus treat-to-target rosuvastatin monotherapy for patients with peripheral artery or polyvascular disease (CARE-PVD Trial)

Overview

Phase
未知
Intervention
Not specified
Conditions
Diseases of the circulatory system
Sponsor
Yonsei University Health System, Severance Hospital
Enrollment
2462
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Ages 19\-80
  • 2\. Patient with arteriosclerotic lower extremity artery disease or multivessel disease
  • 1\) Arteriosclerotic lower extremity artery disease: If any of the following applies
  • \- Ankle\-brachial index \<0\.85 with symptoms of intermittent claudication
  • \- Lower extremity artery stenosis of more than 50% on imaging tests
  • \- History of receiving interventional or surgical treatment for lower extremity artery disease)
  • 2\) Arteriosclerotic multivessel disease: When the following two diseases exist even if there is no lower extremity artery disease
  • \- Coronary artery disease
  • \- History of carotid artery stenosis (more than 50%) or ischemic stroke/transient cerebral ischemia event

Exclusion Criteria

  • 1\. Chronic limb threatening ischemia (Rutherford 4\~6\)
  • 2\. History of acute coronary syndrome or stroke/TIA or lower extremity amputation within 6 months
  • 3\. Acute liver disease or persistent unexplained elevation of serum AST or ALT more than twice the upper limit of normal
  • 4\. Severe renal dysfunction (eGFR \<30 mL/min/1\.73m2\) or dependancy on dialysis
  • 5\. History of allergic or hypersensitivity reaction to statin or ezetimibe or side effects requiring discontinuation of lipid lowering therapy
  • 6\. Solid organ transplant recipients
  • 7\. Pregnant women, potentially pregnant or lactating women
  • 8\. Life expectancy of less than 3 years
  • 9\. When follow\-up for more than 1 year is not possible
  • 10\. Inability to understand or read the consent form

Outcomes

Primary Outcomes

Not specified

Similar Trials